DIANTHUS THERAPEUTICS INC (DNTH) Stock Price, Forecast & Analysis
USA - NASDAQ:DNTH - US2528281080 - Common Stock
DNTH Key Statistics, Chart & Performance
The current stock price of DNTH is 40.85 USD. In the past month the price increased by 14.59%. In the past year, price increased by 74.87%.
DNTH Latest News, Press Relases and Analysis
DNTH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About DNTH
Company Profile
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
Company Info
DIANTHUS THERAPEUTICS INC
7 Times Square, 43Rd Floor
New York City NEW YORK US
Employees: 78
Phone: 19299994055
DIANTHUS THERAPEUTICS INC / DNTH FAQ
Can you describe the business of DIANTHUS THERAPEUTICS INC?
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
Can you provide the latest stock price for DIANTHUS THERAPEUTICS INC?
The current stock price of DNTH is 40.85 USD. The price increased by 15.07% in the last trading session.
Does DIANTHUS THERAPEUTICS INC pay dividends?
DNTH does not pay a dividend.
How is the ChartMill rating for DIANTHUS THERAPEUTICS INC?
DNTH has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is DIANTHUS THERAPEUTICS INC (DNTH) stock traded?
DNTH stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for DIANTHUS THERAPEUTICS INC?
The Revenue of DIANTHUS THERAPEUTICS INC (DNTH) is expected to decline by -58.96% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the short interest for DNTH stock?
The outstanding short interest for DIANTHUS THERAPEUTICS INC (DNTH) is 10.05% of its float.
DNTH Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DNTH. When comparing the yearly performance of all stocks, DNTH is one of the better performing stocks in the market, outperforming 96.22% of all stocks.
DNTH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DNTH. No worries on liquidiy or solvency for DNTH as it has an excellent financial health rating, but there are worries on the profitability.
DNTH Financial Highlights
Over the last trailing twelve months DNTH reported a non-GAAP Earnings per Share(EPS) of -3.48. The EPS decreased by -39.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.88% | ||
| ROE | -23.12% | ||
| Debt/Equity | 0 |
DNTH Forecast & Estimates
20 analysts have analysed DNTH and the average price target is 64.72 USD. This implies a price increase of 58.44% is expected in the next year compared to the current price of 40.85.
For the next year, analysts expect an EPS growth of -32.21% and a revenue growth -58.96% for DNTH